Long-Term Results of Concurrent Chemoradiotherapy for Advanced N2-3 Stage Nasopharyngeal Carcinoma

<div><p>Background</p><p>N-stage is related to distant metastasis in nasopharyngeal carcinoma (NPC) patients. The purpose of this study was to evaluate the efficacy and toxicity of different nedaplatin-based chemotherapy regimens in advanced N2-3 stage NPC patients treated with intensity modulated radiation therapy (IMRT).</p><p>Patients and Methods</p><p>Between April 2005 and December 2009, a total of 128 patients with N2-3 advanced NPC were retrospectively analyzed. Patients were treated with IMRT concurrent with 2 cycles of chemotherapy consisting of either nedaplatin plus paclitaxel (NP group, n = 67) or nedaplatin plus fluorouracil and paclitaxel (NFP group, n = 61). Two to four cycles of adjuvant chemotherapy were then administered every 21 days following concurrent chemoradiotherapy.</p><p>Results</p><p>With a median follow-up of 60 months, the 5-year overall survival (OS), progression-free survival (PFS), local-regional recurrence-free survival (LRRFS), and distant metastasis-free survival (DMFS) for all patients were 81.4%, 71.5%, 87.8% and 82.0%, respectively. No significant difference in PFS (66.6% vs. 76.7%, <i>P</i> = 0.212) and LRRFS rates (89.0% vs. 86.3%, <i>P</i> = 0.664) was observed between the NP and NFP groups. The 5-year OS (75.4% vs. 88.5%, <i>P</i> = 0.046) and DMFS (75.1% vs. 89.0%, <i>P</i> = 0.042) rate were superior in the NFP group compared with the NP group. The NFP group had a higher incidence of grade 3–4 acute toxicities including bone marrow suppression (leukopenia: χ2 = 3.935, <i>P</i> = 0.047; anemia: χ2 = 9.760, <i>P</i> = 0.002; thrombocytopenia: χ2 = 8.821, <i>P</i> = 0.003), and both liver and renal dysfunction (χ² = 5.206, <i>P</i> = 0.023) compared with the NP group. Late toxicities were moderate and no difference was observed between the two groups.</p><p>Conclusion</p><p>IMRT concurrent with nedaplatin-based chemotherapy is an advocated regimen for patients with advanced N2-3 stage NPC. Patients with advanced N2-3 stage may be better candidates for the NFP regimen although this regimen was associated with a high acute toxicity rate.</p>